Table of Contents
I. Data Release 4.0 from the Adolescent Brain Cognitive Development StudySM is available now on the NIMH Data Archive
II. NIDA AIDS Research Program (ARP) Has been Renamed to NIDA HIV Research Program (HRP)
III. Program Officer Position Openings in the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH
IV. Job Opening for Program Officer in Program Officer in the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH to Develop and Manage HIV and Substance Misuse Portfolio.
V. Job Opening (Health Scientist Administrator, Regulatory Affairs)
------
I. Data Release 4.0 from the Adolescent Brain Cognitive Development StudySM is available now on the NIMH Data Archive
The fourth annual curated ABCD Data Release 4.0 is available now on the NIMH Data Archive. In addition to baseline data on the full participant cohort (nearly 12,000 participants), Data Release 4.0 contains early longitudinal data, including 2-year follow-up neuroimaging data (second imaging timepoint), as well as follow-up phenotypic data for the 6-month, 1-year and 18-month visits on the full cohort. Interim data are also available for the 30-month, 3-year and 42-month visits. Smokescreen genotyping array data with TOPMed imputations are available as well. These include common variations, as well as variations associated with addiction, smoking behavior and nicotine metabolism. Also available are ABCD derived scores from linked external school performance and environmental data, including the Stanford Education Data Archive, EPA Smart Location Database, American Community Survey Area Deprivation Index, FBI’s Uniform Crime Report, lead exposure risk and air pollution indices, among others. Authorized users can obtain more information and access the updated data from https://nda.nih.gov/abcd. Full details are in the Release Notes for Data Release 4.0. Please contact Elizabeth A. Hoffman, Ph.D at elizabeth.hoffman@nih.gov for more information.
-------------
II. NIDA AIDS Research Program (ARP) Has been Renamed to NIDA HIV Research Program (HRP)
We are pleased to announce that NIDA is renaming the AIDS Research Program (ARP) to the NIDA HIV Research Program (HRP) to better characterize our scientific investment at the intersection of HIV and substance use disorders. The name change aligns our HIV related science with less stigmatizing language, and reflects more contemporary HIV research and management approaches and priorities. When the ARP program began in 2004, science had only just begun developing improved antiretroviral medications that have transformed HIV from a fatal disease into a manageable and livable condition. NIDA’s HIV research portfolio continues to be the second largest at NIH (after the National Institute of Allergy and Infectious Diseases), and is committed to reducing the stigma that reduces access to care, and can harm mental health. While the name has changed, the mission continues. We will continue to support a wide range of studies, from the basic science of HIV pathogenesis and the immune response in the presence of addictive substances to research on new pre-exposure prophylaxis (PrEP) products among people who use drugs. You can read more about this name change in this blog from NIDA Director Nora D. Volkow.
III. Program Officer Position Openings in Chemistry Pharmacology Physiology (CPP) Branch the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH
Program Officer Opening in Chemistry:
NIDA’s Division of Neuroscience and Behavior (DNB) is recruiting for a Program Officer position within the Chemistry Pharmacology Physiology (CPP) Branch. The Program Officer is expected to develop and oversee a grant portfolio in the rapidly growing field of chemistry and pharmacology of drugs of abuse. The Branch supports all research related to the chemistry and pharmacology of drugs of abuse including the structural dynamics of receptors, computationally-based drug design, intracellular signaling mechanisms, early drug discovery of treatments for addiction, natural product chemistry, and innovative mechanisms of drug delivery. Required areas of expertise includes chemistry, drug design, biophysical and computational approaches, biochemical and neurobiological mechanisms of substance use disorders.
Candidates interested in applying for this position should send a cover letter and curriculum vitae to Dr. Sam Ananthan via email at sam.ananthan@nih.gov
----------
IV. Job Opening for Program Officer in Program Officer in the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH to Develop and Manage HIV and Substance Misuse Portfolio.
The Division of Neuroscience and Behavior (DNB) of the National Institute on Drug Abuse (NIDA) is seeking a dynamic motivated individual to serve as a program officer
DNB develops and supports an extramural research portfolio that will advance the understanding of the genetic, chemical, neurobiological and behavioral mechanisms of addictive drugs and their long-term consequences. The Division supports research on the intersection of HIV and substance use disorders. Drug use is not only a vector for the entry of the virus into the circulation, but it can also facilitate brain entry by affecting blood brain barrier permeability. Additionally, it is associated with risk-taking behavior that increases vulnerability to HIV and other infections. Importantly, substance use can contribute to the course of the disease through independent effects on immune function, by affecting cells that serve as reservoirs of the virus in the brain and through epigenetic mechanisms that regulate latency. Although HIV and addictive drugs can have independent effects on cell biology that contribute to brain diseases, the combination of HIV and drug use can have unique consequences that affect processes such as pain, neurocognitive function and aging. The basic research supported by the DNB provides opportunities to illuminate HIV biology and CNS biology and may provide potential avenues for treating the co-occurrence of HIV and substance use disorder.
The Program Officer will:
- Assist with the development and coordination of a comprehensive research portfolio at the intersection of HIV and substance use disorder
- Provide substantive input into the planning, development, implementation, and evaluation of HIV-related research for the DNB
- Identify opportunities and problem areas, research gaps and relevant program needs and make recommendations regarding HIV-related research
- Organize workshops and scientific panels at conferences
- Serve as DNB liaison with the NIDA HIV Research Program to coordinate funding plans and research opportunities
Candidate Qualifications:
- The ideal candidate will possess a PhD in a branch of the biological sciences and ideally will have expertise in neuroscience and HIV. Interested candidates should send curriculum vitae to Myriam Selmane (selmanem@nida.nih.gov).
-------
V. Job Opening (Health Scientist Administrator, Regulatory Affairs)
The Division of Therapeutics and Medical Consequences (DTMC) of NIDA supports and conducts studies to evaluate the safety and efficacy of new pharmacotherapies, biologics, behavioral therapies, devices, and digital therapeutics for Substance Use Disorders (SUDs). DTMC supports research through peer-reviewed grants and contracts for all stages of medications development including preclinical evaluation of potential therapeutics, clinical trial design and execution, and the preparation of regulatory submissions. The Regulatory Affairs Branch provides expert regulatory guidance and consultation in support of DTMC's medications development efforts.
Regulatory Affairs: The HSA is responsible for providing regulatory expertise and strategies and serves as a liaison between DTMC and other regulatory agencies and organizations (e.g., Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), Institutional Review Boards (IRBs), and Data Safety Monitoring Boards), research sponsors and collaborators, academic investigators, pharmaceutical companies, and clinical research organizations. The HSA participates in the collection and review of study-specific documents (i.e., research protocols, informed consent documents, etc.) and leads the preparation of regulatory submissions (Investigational New Drug Applications (INDs), Drug Master Files (DMFs), New Drug Applications (NDAs), including amendments, supplements, annual reports, and safety reports. The HSA may serve as a Contracting Officer Representative (COR) with delegated authority to act as a Government representative in monitoring specified aspects of contractor performance in meeting the standards set forth in the contract such as technical, performance, and budgetary requirements. The HSA may also serve as Project Officer/Science Officer to provide scientific and administrative stewardship of extramural grant applications.
If Interested: Please submit your cover letter, and CV to Robert Walsh, Branch Chief, Regulatory Affairs Branch, rwalsh@nida.nih.gov, 301.827.5244. Vacancy announcement on USAJOBS.gov is currently scheduled to be advertised on January 18, 2022. The successful completion of all requirements for an M.D. or Ph.D. (or equivalent doctoral degree), in an academic field of health-related sciences is required and salary will be commensurate with experience.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L
No comments:
Post a Comment